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mplantable cardioverter-defibrillators (ICDs) provide life-
aving therapy for selected patients at increased risk of sudden
ardiac death. In the 3 decades since the first human implant,
illions of patients have undergone ICD implantation, and
nnumerable lives have been saved. Critical to the widespread
cceptance, distribution, and safe implantation of the device
ave been remarkable design and engineering advances that
ave greatly reduced the risks associated with device implan-
ation. The low implant risk in combination with strong
cientific evidence supporting ICD implantation in numerous
rimary prevention populations has produced a growing
chronic” ICD population. As a result, clinicians are increas-
ngly faced with ICD lead management issues related to lead
erformance, infection, or the need for device upgrade.
See page 646
Removal or extraction of a previously implanted ICD
ead is sometimes required. Significant efforts to develop
ools and techniques for the removal of problematic leads
ere first undertaken in the 1980s. As a result, a substantial
toolbox” is now available to the extracting physician,
ncluding traction devices such as locking stylets and snares,
nd a variety of specialized sheaths that use mechanical,
aser-assisted, or electrosurgical methods to assist with
emoval of fibrotic tissue that impedes lead extraction.
Given the significant advances in extraction technology and
he increasing experience of the operators, overreliance on
utdated extraction studies that describe extraction-associated
orbidity and mortality could provide a misleading perspec-
ive. In this issue of the Journal, Maytin et al. (1) report on a
etrospective cohort of 348 patients undergoing 349 ICD lead
xtractions (mean implant duration of 27.5 months) at 5
igh-volume extraction centers betweenMay 2005 and August
009. All extractions were performed to manage recalled
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Medical Device Safety Institute and Cardiovascular Institute, Beth Israeld
eaconess Medical Center, Boston, Massachusetts. The authors have reported that
hey have no relationships to disclose.edtronic (Minneapolis, Minnesota) Sprint Fidelis ICD
eads, nearly one-half with evidence of lead fracture and
ne-fourth with evidence of infection before extraction. Simple
raction was used in 49.7% of cases, with additional specialized
xtraction tools required in the remainder. The authors report
omplete removal of the index lead in every case with no major
omplications or deaths. Minor complications were observed
n only 0.57% of patients.
Although the authors are to be congratulated for their
emarkable clinical performance, it is critical to understand
hat this report stands in contrast to other large studies of
ead extraction. Older registry data from the U.S. and
urope presented in 2000 and involving 7,823 extraction
rocedures and involving close to 12,833 pacemaker and
CD leads demonstrated a major complication rate of 1.6%
2). Implant duration of the oldest lead, ICD leads (com-
ared with pacemaker leads), female sex, low-volume ex-
raction hospitals, and the need for laser assistance were
dentified as risk factors for adverse outcomes (2). Byrd et al.
3) reported the results of the PLEXES (Pacemaker Lead
xtraction With the Excimer Sheath) trial, involving 2,561
acemaker and ICD leads in 1,684 patients undergoing laser
ead extraction. They experienced a major complication rate of
.9% and an in-hospital mortality rate of 0.8%.
More recently, Wazni et al. (4) reported a 97.7% clinical
uccess rate, a 1.4% major adverse event rate, a 0.28%
rocedure-related mortality rate, and a 1.86% in-hospital
ortality rate among 2,405 laser-assisted lead extractions
erformed in 1,449 patients. Interestingly, the Wazni et al.
eport (4) includes some of the same authors and institutions as
he Maytin et al. report (1) during an overlapping time frame,
uggesting that some patients may appear in both reports. A
eview of device-assisted lead extraction adverse events re-
orted to U.S. Food and Drug Administration revealed 57
eaths and 48 serious cardiovascular injuries between 1995 and
008, with nearly 40% occurring in the final 2 study years (5).
ost notable was the conclusion that some extraction injuries
annot be mitigated by emergency cardiac surgery.
It is difficult to reconcile the absence of “major” compli-
ations and the 1% rate of “minor” complications for a
rocedure as complex as a lead extraction, as reported by
aytin et al. (1), when reports of large well-conducted
tudies repeatedly cite “major” complication rates related to
impler procedures such as ICD implantation and generator
hanges that exceed 4% (6,7). One explanation may relate to
erminology: even “minor” extraction complications can be
linically important. For example, the Heart Rhythm Soci-
ty Transvenous Lead Extraction Consensus Document (2)
efines minor complications as including hematoma at the
mplant site requiring reoperation, venous thrombosis of
mplant veins requiring medical intervention, vascular repair at
he extraction site, blood loss requiring transfusion, pulmonary
mbolism not requiring surgical intervention, and hemody-
amically significant air embolism. Long-term studies have
emonstrated that immediate post-procedure complications
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Extracting Guidance From Extraction Data August 17, 2010:651–2ssociated with ICD implantation are associated with in-
reased mortality at 180 days, suggesting that focusing only on
ajor complications may provide a misleading perspective on
he safety of the extraction procedure (6).
Clinical management of patients with Medtronic Sprint
idelis leads remains a challenge. Medtronic’s February 2010
pdate estimates a 7.9% lead failure rate at 57 months
ost-implantation (8), whereas other studies suggest an in-
reasing annual risk of Fidelis failure (9). When leads do fail,
nappropriate shocks are experienced by more than one-half of
he patients, although algorithms have been developed that can
dentify impending fractures earlier, reducing the risk of inap-
ropriate shocks and other untoward clinical events (10,11).
How should patients with a Medtronic Sprint Fidelis lead
e managed in light of the Maytin et al. (1) report in this issue
f the Journal? First, it is important to recognize that this study
as not an evaluation of prophylactic Fidelis explantation.
ndeed, nearly three-fourths of the patients had a bona fide
ndication for lead removal, either a lead fracture or infection.
econd, although the failure rate of the Fidelis lead is high
ompared with historical standards, it is the minority of
atients who are affected by actual lead performance issues.
herefore, a strategy that includes prophylactic extraction of all
idelis leads is not only likely to result in unnecessary
xtraction-related deaths, but will also needlessly expose nu-
erous patients to potentially unnecessary procedures and the
ttendant complications. More specifically, if the 143,000
atients in the U.S. who still have Fidelis leads implanted (12)
ere to undergo prophylactic lead explantation with an esti-
ated mortality rate of 0.25% to 0.50%, 350 to 720 procedure-
elated deaths would be expected. To date, 13 deaths “possibly”
r “likely” related to Fidelis failure have been confirmed, and 4
f the 13 were related to lead extraction (13).
Because unique patient and clinician factors affect the
alculus of which clinical approach is best for individual
atients, clinical recommendations must be individualized,
s advised by the Heart Rhythm Society Task Force on
ead Performance and Policies (14). A number of factors
hould contribute to the clinical decision making, including
atient prognosis, surgical risk of the revision/replacement
rocedure, patient anxiety over lead failure, history of
entricular arrhythmia, and estimated future risk of arrhyth-
ia. Perhaps most important among patient risk factors is
he degree of pacemaker dependence because lead failure in
pacemaker-dependent patient is more likely to result in
ife-threatening complications.
Currently, it appears advisable to consider patients who
re pacemaker dependent (defined as a hemodynamically
nstable rhythm in the absence of pacing) or who have
onfirmed or suspected Fidelis fractures for system revision.
n most cases, lead extraction with implantation of a new
CD lead will be the preferred method, although the
ddition of a new ICD lead with abandonment/capping of
he old Fidelis lead may be an option in some patients.
otably, however, for the majority of patients who have
ormally functioning leads at follow-up, active remote
K
lonitoring with automated lead integrity checks remains a
iable, appropriate management option.
The tools and techniques for ICD lead extraction have
reatly improved. However, it is critical that clinicians and
atients have realistic expectations regarding clinical outcomes
fter extraction and recognize that life-threatening complica-
ions can and do occur. Patient care must be individualized. It
s gratifying to see that lead extraction can be performed with
ncreasingly good results, but this is not a prescription for
xtracting every normally functioning Fidelis lead.
eprint requests and correspondence: Dr. William H. Maisel,
edical Device Safety Institute, 185 Pilgrim Road, Baker 4, Boston,
assachusetts 02215. E-mail: wmaisel@bidmc.harvard.edu.
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